Holen Sie sich die Stockscreener-App
53.77
2.54%
1.33
Handel nachbörslich:
53.80
0.03
+0.06%
Schlusskurs vom Vortag:
$52.44
Offen:
$52.72
24-Stunden-Volumen:
1.37M
Relative Volume:
0.60
Marktkapitalisierung:
$5.12B
Einnahmen:
$170.10M
Nettoeinkommen (Verlust:
$-239.59M
KGV:
-19.20
EPS:
-2.8
Netto-Cashflow:
$-191.20M
1W Leistung:
-2.38%
1M Leistung:
+4.25%
6M Leistung:
+4.06%
1J Leistung:
+29.79%
1-Tages-Spanne:
$52.10
$54.27
1-Wochen-Bereich:
$52.10
$55.41
52-Wochen-Spanne:
$30.04
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Firmenname
Crispr Therapeutics Ag
Sektor
Branche
Telefon
(617) 315-4600
Adresse
BAARERSTRASSE 14, ZUG
Vergleichen Sie CRSP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
53.77 | 5.00B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | JP Morgan | Overweight |
| 2025-02-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Hochstufung | TD Cowen | Sell → Hold |
| 2025-02-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-08-02 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-28 | Fortgesetzt | Guggenheim | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-11 | Herabstufung | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Eingeleitet | Mizuho | Buy |
| 2023-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-04-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-03-17 | Eingeleitet | Bryan Garnier | Buy |
| 2023-03-07 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-08-09 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-04-21 | Hochstufung | Jefferies | Hold → Buy |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2020-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-10 | Bestätigt | Needham | Buy |
| 2020-12-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-07-28 | Bestätigt | Needham | Buy |
| 2020-07-14 | Eingeleitet | SunTrust | Buy |
| 2020-06-15 | Bestätigt | Canaccord Genuity | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Eingeleitet | Jefferies | Buy |
| 2019-07-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-06-10 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-14 | Eingeleitet | William Blair | Mkt Perform |
| 2019-01-28 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-22 | Herabstufung | Citigroup | Neutral → Sell |
Alle ansehen
Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten
Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize - Benzinga
Crispr Therapeutics: Prospects For 2026Why I Believe Casgevy Is Key (NASDAQ:CRSP) - Seeking Alpha
CRISPR Therapeutics AG Stock Analysis and ForecastInsider Trading Compliance & Unlock Free Weekly Portfolio Checkups - earlytimes.in
CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next - ts2.tech
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com
Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks - Benzinga
Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry? - The Globe and Mail
Chardan maintains a buy recommendation on CRISPR Therapeutics AG (CRSP) - MSN
Chardan Maintains A Buy Recommendation On CRISPR Therapeutics AG (CRSP) - Finviz
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know - sharewise.com
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock - sharewise.com
Discipline and Rules-Based Execution in CRSP Response - Stock Traders Daily
Contrarius Global Equity Fund’s Thoughts on CRISPR Therapeutics’ (CRSP) Gene Editing Therapy - Insider Monkey
CRISPR Therapeutics Reports Strong 90% Response Rate and Lupus Remission in Landmark Zugo-Cel Update - Finviz
CRISPR Therapeutics reports strong 90% response rate and lupus remission in landmark Zugo-Cel update - MSN
CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors - ts2.tech
CRISPR Therapeutics AG (CRSP) Stock: ARK Invest Adds Shares as Wall Street Weighs Zugo‑cel Data, Insider Sale, and 2026 Catalysts - ts2.tech
Cathie Wood’s ARK boosts CRISPR stock with significant buy - Investing.com
CRISPR Therapeutics (CRSP) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
These 2 Healthcare Stocks Beat the Market in 2025. Should You Buy Them in 2026? - Finviz
CRISPR Therapeutics (CRSP): Reassessing Valuation After Positive Zugo‑cel Data and New Eli Lilly Collaboration - simplywall.st
Is CRISPR Therapeutics stock yesterday's news? - MSN
Is CRISPR Therapeutics Stock Yesterday's News? - Finviz
CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know - sharewise.com
CRISPR Therapeutics AG (CRSP) stock falls amid market uptick: What investors need to know - MSN
Citizens Reiterates CRISPR Therapeutics (CRSP) Market Outperform Recommendation - Nasdaq
Crispr Therapeutics Insider Sold Shares Worth $559,549, According to a Recent SEC Filing - marketscreener.com
CRISPR Therapeutics (CRSP) CFO reports 10,000-share sale in Form 4 - Stock Titan
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term - Finviz
CRSP Maintains Market Outperform Rating: Latest Analyst Insights | CRSP Stock News - GuruFocus
CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies - Finviz
Early but Compelling CTX112 Data Underpin Buy Rating and $80 Target for CRISPR Therapeutics - TipRanks
Citizens Jmp Reaffirms Market Outperform Rating for CRISPR Therapeutics (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Receives Buy Rating from Needham & Company LLC - MarketBeat
CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies - Sahm
CRISPR Therapeutics CRISPR Therapy Shows 90% Response Rate In Aggressive Blood Cancer - Sahm
CRISPR Therapeutics: Early Autoimmune Promise, Best-in-Class Oncology Data, and Eli Lilly Partnership Support Buy Rating - TipRanks
Crispr Therapeutics provides updates on zugo-cel - TipRanks
CRISPR Says Zugo-cel Well-Tolerated in Phase 1 Autoimmune Rheumatic Diseases Trial - marketscreener.com
CRSP Advances Zugo-cel CAR T Therapy with Promising Clinical Res - GuruFocus
CRISPR Therapeutics Reports Promising Early Results for Zugo-cel in Autoimmune Diseases and Oncology Trials - Quiver Quantitative
CRISPR Therapeutics Provides Broad Update on Zugocaptagene - GlobeNewswire
Entry Recap: Is CRISPR Therapeutics AG stock positioned for long term growth2025 Key Lessons & Real-Time Chart Pattern Alerts - Улправда
How Investors May Respond To CRISPR Therapeutics (CRSP) Earnings Amid Slow Casgevy Uptake Concerns - simplywall.st
What dividend safety rating applies to CRISPR Therapeutics AG (1CG) stockProfit Target & Technical Confirmation Trade Alerts - Улправда
Investor Mood: Is CRISPR Therapeutics AG stock a smart buy before Fed meetingInsider Selling & High Accuracy Investment Signals - Улправда
Trading the Move, Not the Narrative: (CRSP) Edition - news.stocktradersdaily.com
CRISPR Therapeutics AG (CRSP) falls more steeply than broader market: What investors need to know - MSN
Finanzdaten der Crispr Therapeutics Ag-Aktie (CRSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):